New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Highly Regulated (List I)Translated

VILDAMETFOR

50MG/1000MG/Film-coated Tablet/VIDAGLIPTINE/METFORMINE CHLORHYDRATE
EL KENDI DU MEDICAMENT
ManufacturerVerified lab

EL KENDI DU MEDICAMENT

Public retail price
N/ADZD
Reference price (TR): 1741.20 DZD

Identification

Active ingredient (INN)
VIDAGLIPTINE/METFORMINE CHLORHYDRATE
Internal code
14 A 360
Country of Origin
Algeria
Pharmaceutical form
Film-coated Tablet
Prescription List
Highly Regulated (List I)
Packaging
b/30
VILDAMETFOR
Clinical View
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Associated Conditions

Diabetes ketoacidosis History of pancreatitis

Combination with a sulphonylurea Insulin-dependent diabetes Severe hepatitis Heart failure Hepatic impairment Moderate to severe renal impairment Hemodialysis patient Subject under 18 Serum transaminases > 3 times the normal upper limit.

Mechanism of Action

Mechanism of action

Vildagliptin, via a potent and selective inhibitory effect of DPP-4, amplifies the incretin effect on the Langerhans islets.

Vildagliptin administration results in a rapid and complete inhibition of the activity of DPP-4, resulting in an increase in the endogenous fasting and postprandial levels of the GLP-1 (glucagon -like peptide 1) and GIP (glucose -dependent insulintropic polypeptide) hormones.

By increasing endogenous levels of these hormones incretins, vildagliptin improves the sensitivity of beta cells to glucose, thereby improving insulin glucose-dependent secretion.

By increasing endogenous concentrations of

GLP-1, vildagliptin also improves the sensitivity of alpha cells to glucose, which induces a more appropriate secretion of glucose-dependent glucagon.

In the case of hyperglycaemia, this improvement in the hepatic ratio of glucose-related factors, the insulin/glucosergic mechanisms increase the insulin/glucose agent, which causes the insulin/glucose agent to decrease the insulin/glucose agent to the insulin ratio.

Adverse Effects

  • Hypoglycaemia (Uncommon)
  • Liver status (abnormality) (Uncommon)
  • Glycaemia decreased (Common)
  • ASAT (increase)
  • ALT (increase)
  • Pruritus (Common)
  • Urticaria (Uncommon)
  • Dermatitis (Common)
  • Hyperhidrosis (Common)
  • Rash (Common)
  • Exfoliative dermatitis Bully dermatosis Bully pemphigoid
  • Frisher (Uncommon)
  • Asthenia (Common)
  • Fatigue (Uncommon)
  • Peripheral edema (Common)
  • Hepatitis Hepatitis Angioedema (Rare)
  • Weight (increase) (Uncommon)
  • Blurty vision (Common)
  • Rhinophyryngitis (Very common)
  • Feeling dizzy (Common)
  • Skin vasculitis Abdominal pain (Common)
  • Gastroesophageal reflux (Common)
  • Diarrhoea (Common)
  • Nausea (Common)
  • Flatulence (Uncommon)
  • Constipation (Common)
  • Vomiting (Common)
  • Pancreatitis (Rare)
  • Abnormal liver function (Rare)
  • Joint pain (Common)
  • Muscle pain (Common)
  • Headache (Common)
  • Trembling (Common)
  • Upper respiratory tract infection (Common)
  • Erection disorder (Uncommon).

Alternatives